Karmanos Cancer Institute Database
A TINA.org investigation revealed that numerous cancer centers in the U.S. are deceptively using patient testimonials in their marketing materials, that is, testimonials that promote anecdotal, atypical patient results without clearly and conspicuously disclosing what the generally expected results for a patient in a similar situation would be. Moreover, within this sampling of deceptive testimonials many also promote clinical trials (i.e., research endeavors with no guarantee of therapeutic benefit), as well as novel treatments, such as immunotherapy and/or experimental procedures, without clearly and conspicuously disclosing their limitations, risks and relative rarity.
Below is a sampling of TINA.org’s findings for Karmanos Cancer Institute. If any of the testimonials attribute the patient’s success to a clinical trial, the entry appears in bold italics.
This center was notified of TINA.org’s findings on October 22nd, 2018.
To learn more about the statistics and criteria used in TINA.org’s investigation, as well as other information, click here.
|Name||Cancer Type||Testimonial||SEER 5-Year Survival Rate*|
|Arianne B.||Brain||Magazine (July 2014)||33.2%|
|Bill S.||Lung, Stage 3A||Magazine (December 2016)||29.7%|
|Bonnie E.||Lung, Stage 4||Feature in 2011 Calendar||4.7%|
|Jessica D.||Colorectal, Stage 4||Facebook 1 (link below)||13.8%|
|Jessica D.||Colorectal, Stage 4||Facebook 2 (link below)||13.8%|
|Jessica D.||Colorectal, Stage 4||Twitter (link below)||13.8%|
|Jessica D.||Colorectal, Stage 4||Website 1||13.8%|
|Jessica D.||Colorectal, Stage 4||Video (as seen on website 2)||13.8%|
|Jessica D.||Colorectal, Stage 4||Video (as seen on Youtube)||13.8%|
|Joe S.||Lung, Stage 4||Website||4.7%|
|Lateia S.||Esophageal, Stage 2||Magazine (September 2013)||23.6%|
|Madeline T.||Liver||Magazine (January 2018)||17.7%|
|Mary A.||Colon, Stage 4||Website||13.8%|
|Ron L.||Throat, Stage 4||Magazine (Spring 2009)||39.1%|
|Shawn G.||Colon, Stage 4||Magazine (April 2014)||13.8%|
|Susan T.||Colon, Stage 4||Magazine (September 2017)||13.8%|
|Tom K.||Acute Myeloid Leukemia (AML)||Magazine (April 2013)||27.4%|